Willaim Blair Advises Coria on Sale
William Blair and Company announces the success of its client, Coria Laboratories, Ltd., a subsidiary of DFB Pharmaceuticals, in connection with its sale to Valeant Pharmaceuticals International for $95 million in cash. William Blair & Company served as financial advisor to Coria Laboratories for the transaction.
Coria Laboratories, Ltd. is a pharmaceutical company specializing in research, development, and marketing of high-quality dermatology products for the treatment of diseases affecting the skin, hair, and nails. Coria has a broad portfolio of branded prescription and over-the-counter dermatology products, including a variety of lotions, creams, moisturizers, and shampoo products.
DFB Pharmaceuticals is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide.
Valeant Pharmaceuticals International is a specialty pharmaceutical company that develops, manufactures, and markets a range of pharmaceutical products in the areas of neurology and dermatology.
Coria Laboratories, Ltd. is a pharmaceutical company specializing in research, development, and marketing of high-quality dermatology products for the treatment of diseases affecting the skin, hair, and nails. Coria has a broad portfolio of branded prescription and over-the-counter dermatology products, including a variety of lotions, creams, moisturizers, and shampoo products.
DFB Pharmaceuticals is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide.
Valeant Pharmaceuticals International is a specialty pharmaceutical company that develops, manufactures, and markets a range of pharmaceutical products in the areas of neurology and dermatology.
